Gleevec and Recurrent leg pain and cramping - from FDA reports


Summary

Recurrent leg pain and cramping is found among people who take Gleevec, especially for people who are female, 60+ old , have been taking the drug for < 1 month, also take medication Ambien, and have Sarcoma. This review analyzes which people have Recurrent leg pain and cramping with Gleevec. It is created by eHealthMe based on reports of 26,043 people who have side effects when taking Gleevec from FDA , and is updated regularly.

What to expect?

If you take Gleevec and have Recurrent leg pain and cramping, find out what symptoms you could have in 1 year or longer.

You are not alone!

Join a support group for people who take Gleevec and have Recurrent leg pain and cramping

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>

On Sep, 21, 2017

26,043 people reported to have side effects when taking Gleevec.
Among them, 9 people (0.03%) have Recurrent leg pain and cramping


Number of reports submitted per year:

Could Gleevec cause Recurrent leg pain and cramping?

Time on Gleevec when people have Recurrent leg pain and cramping *:

  • < 1 month: 80 %
  • 1 - 6 months: 20 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Recurrent leg pain and cramping when taking Gleevec *:

  • female: 75 %
  • male: 25 %

Age of people who have Recurrent leg pain and cramping when taking Gleevec *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 14.29 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 85.71 %

Top conditions involved for these people *:

  • Sarcoma (3 people, 33.33%)
  • Stress And Anxiety (1 person, 11.11%)
  • Pain (1 person, 11.11%)
  • Chronic Phase Chronic Myeloid Leukaemia (1 person, 11.11%)
  • Carcinoid Tumor Of The Gastrointestinal Tract (1 person, 11.11%)

Top co-used drugs for these people *:

  • Valsartan (1 person, 11.11%)
  • Metformin (1 person, 11.11%)
  • Melatonin (1 person, 11.11%)
  • Lipitor (1 person, 11.11%)
  • Ambien (1 person, 11.11%)

Top other side effects for these people *:

  • Urticaria (4 people, 44.44%)
  • Stress And Anxiety (4 people, 44.44%)
  • Platelet Count Increased (4 people, 44.44%)
  • Peripheral Arterial Occlusive Disease (4 people, 44.44%)
  • Panic Reaction (4 people, 44.44%)

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

Do you have Recurrent leg pain and cramping when taking Gleevec?

Expand the study to include all drugs with the same ingredients

Recurrent leg pain and cramping and drugs with ingredients of imatinib mesylate.

Expand the study to include reports from both FDA and eHealthMe

Recurrent leg pain and cramping and Gleevec from FDA and eHealthMe reports

Gleevec

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). (latest outcomes from Gleevec 26,410 users)

Recurrent leg pain and cramping

Recurrent leg pain and cramping (repeated leg pain and muscle contraction) has been reported by people with osteoporosis, chronic myeloid leukaemia, high blood pressure, high blood cholesterol (latest reports from 3,063 Recurrent leg pain and cramping patients).

Browse all side effects of Gleevec

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Recurrent leg pain and cramping

Recurrent leg pain and cramping

Could your condition cause Recurrent leg pain and cramping

Recurrent leg pain and cramping

Related studies

What would happen?

Forecast new side effects and undetected conditions when you take Gleevec and have Recurrent leg pain and cramping.

Questions to the study

More questions >

User reviews to the study

More reviews >